DE60333201D1 - Verfahren zur herstellung von proteinen - Google Patents

Verfahren zur herstellung von proteinen

Info

Publication number
DE60333201D1
DE60333201D1 DE60333201T DE60333201T DE60333201D1 DE 60333201 D1 DE60333201 D1 DE 60333201D1 DE 60333201 T DE60333201 T DE 60333201T DE 60333201 T DE60333201 T DE 60333201T DE 60333201 D1 DE60333201 D1 DE 60333201D1
Authority
DE
Germany
Prior art keywords
proteins
production
transient expression
secreted protein
protein therefrom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333201T
Other languages
English (en)
Inventor
Gilbert Gorr
Heike Launhardt
Birgit Berg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eleva GmbH
Original Assignee
Greenovation Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020020382 external-priority patent/EP1398383A1/de
Application filed by Greenovation Biotech GmbH filed Critical Greenovation Biotech GmbH
Application granted granted Critical
Publication of DE60333201D1 publication Critical patent/DE60333201D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
DE60333201T 2002-09-12 2003-09-08 Verfahren zur herstellung von proteinen Expired - Lifetime DE60333201D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20020020382 EP1398383A1 (de) 2002-09-12 2002-09-12 Verfahren zur Herstellung von Proteinen
EP03015881 2003-07-11
PCT/EP2003/009959 WO2004024927A1 (en) 2002-09-12 2003-09-08 Protein production method

Publications (1)

Publication Number Publication Date
DE60333201D1 true DE60333201D1 (de) 2010-08-12

Family

ID=31995519

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60333201T Expired - Lifetime DE60333201D1 (de) 2002-09-12 2003-09-08 Verfahren zur herstellung von proteinen

Country Status (9)

Country Link
EP (1) EP1539966B1 (de)
AT (1) ATE472604T1 (de)
AU (1) AU2003270152A1 (de)
DE (1) DE60333201D1 (de)
DK (1) DK1539966T3 (de)
ES (1) ES2347325T3 (de)
PT (1) PT1539966E (de)
SI (1) SI1539966T1 (de)
WO (1) WO2004024927A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57466B1 (sr) 2003-11-05 2018-09-28 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
CN101115773B (zh) 2005-02-07 2015-06-10 罗氏格黎卡特股份公司 结合egfr的抗原结合分子,编码它的载体,及其应用
CN101291954B (zh) 2005-08-26 2013-03-27 罗氏格黎卡特股份公司 具有改变的细胞信号传导活性的修饰的抗原结合分子
SE529610C2 (sv) 2006-02-13 2007-10-02 Alfa Laval Corp Ab Centrifugalseparator
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
AU2010288469A1 (en) 2009-08-31 2012-03-01 Roche Glycart Ag Affinity-matured humanized anti CEA monoclonal antibodies
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
TW201209063A (en) 2010-08-13 2012-03-01 Roche Glycart Ag Anti-tenascin-C A2 antibodies and methods of use
JP5793568B2 (ja) 2010-08-13 2015-10-14 ロシュ グリクアート アーゲー 抗ｆａｐ抗体及び使用の方法
WO2012107416A2 (en) 2011-02-10 2012-08-16 Roche Glycart Ag Improved immunotherapy
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
PE20141017A1 (es) 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
DK2748202T3 (en) 2011-08-23 2018-09-17 Roche Glycart Ag BISPECIFIC ANTI-BINDING MOLECULES
CN103890006A (zh) 2011-08-23 2014-06-25 罗切格利卡特公司 抗mcsp抗体
MX365382B (es) 2012-08-07 2019-05-31 Roche Glycart Ag Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
MX2015010789A (es) 2013-02-26 2015-11-26 Roche Glycart Ag Anticuerpos anti-pcsm.
CA2981711A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
AU2016326738B2 (en) 2015-09-24 2023-08-31 Abvitro Llc HIV antibody compositions and methods of use
CN108290954B (zh) 2015-12-09 2022-07-26 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
EP3178848A1 (de) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
CN108699155B (zh) 2016-03-01 2023-03-21 豪夫迈·罗氏有限公司 具有改变的细胞死亡诱导的奥滨尤妥珠单抗变体
EP3455252B1 (de) 2016-05-11 2022-02-23 F. Hoffmann-La Roche AG Modifizierte anti-tenascin-antikörper und verfahren zur verwendung
BR112019022558A2 (pt) 2016-06-02 2020-05-19 Hoffmann La Roche anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção
EP3252078A1 (de) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
CA3059468A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
MX2020004933A (es) 2017-11-14 2021-01-08 Arcellx Inc Polipéptidos que contienen dominios d y sus usos.
JP7356435B2 (ja) 2017-11-14 2023-10-04 アーセルクス インコーポレイテッド 多機能性免疫細胞療法
US20210221908A1 (en) 2018-06-03 2021-07-22 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
CN109295068B (zh) * 2018-09-14 2021-04-09 昆明理工大学 一种三七类甜蛋白基因PnTLP2及应用
CN109234284B (zh) * 2018-09-14 2021-04-09 昆明理工大学 一种三七类甜蛋白基因PnTLP5及应用
EP3831849A1 (de) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispezifische antikörper gegen ceacam5 und cd47
JP2023551353A (ja) 2020-10-13 2023-12-08 アヴィタイド エルエルシー ３へリックスバンドルタンパク質の親和性リガンドライブラリー及びその使用
WO2022081775A1 (en) 2020-10-13 2022-04-21 Avitide LLC Aav8 affinity agents
WO2022178396A1 (en) 2021-02-19 2022-08-25 Avitide LLC Aav2 affinity agents
CN117222412A (zh) 2021-04-23 2023-12-12 豪夫迈·罗氏有限公司 Nk细胞接合剂相关的不良反应的预防或减轻
WO2023122327A2 (en) 2021-12-24 2023-06-29 Avitide LLC Chi domain affinity ligands and agents
WO2024025911A1 (en) 2022-07-29 2024-02-01 Avitide LLC An affinity agent comprising a ligand that binds vce and comprises seq id no: 1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19947290A1 (de) * 1999-10-01 2001-04-19 Greenovation Pflanzenbiotechno Verfahren zur Herstellung proteinöser Substanzen

Also Published As

Publication number Publication date
PT1539966E (pt) 2010-09-14
SI1539966T1 (sl) 2010-10-29
AU2003270152A1 (en) 2004-04-30
WO2004024927A1 (en) 2004-03-25
DK1539966T3 (da) 2010-10-04
ATE472604T1 (de) 2010-07-15
EP1539966A1 (de) 2005-06-15
EP1539966B1 (de) 2010-06-30
ES2347325T3 (es) 2010-10-28

Similar Documents

Publication Publication Date Title
DE60333201D1 (de) Verfahren zur herstellung von proteinen
DE60230040D1 (de) Fermentationsverfahren zur herstellung von l-aminosäuren unter verwendung von stämmen aus der familie der enterobacteriaceae
DE60239669D1 (de) Sojabohnenprotein, verfahren zu seiner herstellung sowie dessen säure enthaltende proteinnahrungsmittel
DE60335195D1 (de) Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon
SG149000A1 (en) Gag binding proteins
DE60125218D1 (de) Verfahren zur herstellung von humanem serumalbumin unter verwendung eines aufwarmschrittes
ATE520781T1 (de) Verfahren zur veränderung des gehalts von speicherstoffen in pflanzen
DE69935978D1 (de) Kulturmedium zur kultivierung tierischer zellen und verfahren zur herstellung von proteinen durch dessen verwendung
DE60139122D1 (de) Verfahren zur produktion von natürlichen medizin präparaten
DE59601822D1 (de) Verfahren zur herstellung von weizenproteinhydrolysaten
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
DE60113049D1 (de) Verfahren zur Herstellung von natürlichem Käse
ATE387497T1 (de) Samenspezifische 7s-alpha-promoter zur expression von genen in pflanzen
ATE351911T1 (de) Verfahren zur herstellung von heterologen proteinen in fungi
DE60120665D1 (de) Verfahren zur herstellung von geschnittenem tabak und herstellungssystem dafür
RS50075B (sr) Postupak za proizvodnju heterolognih proteinskih supstanci u biljnom materijalu
ATE499845T1 (de) Weisses proteinklebermehl und verfahren für seine verwendung
DE69630524D1 (de) Methoden zur aufreinigung von authentischem igf aus hefewirtszellen
ATE220714T1 (de) Verfahren zur herstellung von proteinen
DE50301559D1 (de) Verfahren zur herstellung von tocotrienol-angereicherten präparationen
DE60228588D1 (de) Verfahren zur konstruktion von künstlicher vegetation nach dem vorbild von natürlichem laub
DE60117754D1 (de) Verfahren zur herstellung von rekombinantem trypsin
ATE171711T1 (de) Cyclohexapeptide und deren mischungen, verfahren zur herstellung sowie deren verwendung
ATE235461T1 (de) Verfahren zur herstellung von 3-cyano-2,4- dihalogen-5-fluor-benzoesäuren